Provided by Tiger Trade Technology Pte. Ltd.

First Advantage Corp.

21.22
+0.80003.92%
Post-market: 21.220.00000.00%19:30 EDT
Volume:1.08M
Turnover:22.72M
Market Cap:3.64B
PE:146.13
High:21.25
Open:20.67
Low:20.58
Close:20.42
52wk High:25.15
52wk Low:8.82
Shares:171.54M
Float Shares:93.74M
Volume Ratio:0.76
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1452
EPS(LYR):-0.2011
ROE:1.94%
ROA:2.82%
PB:2.81
PE(LYR):-105.54

Loading ...

Press Release: Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Dow Jones
·
Aug 07

First Advantage Raised to Buy from Hold by Needham

Dow Jones
·
Aug 07

First Advantage upgraded to Buy from Hold at Needham

TIPRANKS
·
Aug 07

First Advantage Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

First Advantage boosts outlook and adds new director

TIPRANKS
·
Aug 06

First Advantage Q2 Revenue and Profit Beat, Lifts 2026 Outlook

Reuters
·
Aug 06

First Advantage raises 2026 adjusted EPS view to $1.23-$1.29 from $1.15-$1.25

TIPRANKS
·
Aug 06

GUIDANCE: (FA) First Advantage Expects 2026 Revenue Range $1.67B to $1.71B, vs. FactSet Est of $1.67B

MT Newswires Live
·
Aug 06

First Advantage Q2 Adj. EPS $0.35 Beats $0.28 Estimate, Sales $448.800M Beat $415.028M Estimate

Benzinga Earnings
·
Aug 06

First Advantage Q2 Revenue USD 448.8 Million Vs. IBES Estimate USD 415 Million

Reuters
·
Aug 06

First Advantage Reports Second Quarter 2026 Results

THOMSON REUTERS
·
Aug 06

First Advantage Corporation - Outlook Fy2026 Adj EPS $1.23-$1.29

THOMSON REUTERS
·
Aug 06

First Advantage Q2 Adjusted EPS USD 0.35 VS. Ibes Estimate USD 0.28

THOMSON REUTERS
·
Aug 06

First Advantage Q2 Cash Flow from Operations USD 73.6 Million

THOMSON REUTERS
·
Aug 06

First Advantage Q2 Adjusted Net Income USD 61.4 Million VS. Ibes Estimate USD 50.4 Million

THOMSON REUTERS
·
Aug 06

Analyst Sees Larimar as Undervalued on Nomlabofusp’s Strong Efficacy and On‑Track BLA, Reiterates Buy Rating Ahead of 2027 FA Launch

TIPRANKS
·
Aug 05

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

GlobeNewswire
·
Aug 04

First Advantage price target raised to $21 from $17 at RBC Capital

TIPRANKS
·
Aug 03

RBC Capital Adjusts First Advantage Price Target to $21 From $17, Maintains Sector Perform Rating

MT Newswires Live
·
Aug 03

Press Release: Design Therapeutics Provides Restore-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 03